According to diabetes news, Amylin Pharmaceuticals Inc have released a report that says their once per week Byetta medicine could lead to significant improvements in blood sugar levels . The medication, to treat type 2 diabetes patients, has recently been through clinical trials .
Byetta, chemical name exenatide, was found to drop blood sugar levels by approximately 2 per cent, more than the 1.5 per cent drop reported for the only other approved drug of this class, regular Byetta.
The Chief Executive of Amylin, Daniel Bradbury, reportedly commented: “Exenatide once-weekly is poised to become best in class.” Byetta is under threat from an experimental Roche drug known as liraglutide.
The race is on for pharmaceutical companies to progress diabetes drugs to the next phase of efficiency. A variety of biotechnology and research firms have made important breakthroughs in the diabetes sphere in recent years.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…